Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| William Hawkins | M | 70 | 5 Jahre | |
| Maria Freire | M | 69 | 3 Jahre | |
| Jesus Mantas | M | 55 | 5 Jahre | |
| Michael McDonnell | M | 60 | 4 Jahre | |
| Douglas Fambrough | M | 55 |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 Jahre |
| Dina Chaya | M | 52 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 3 Jahre |
| Bali Muralidhar | M | 44 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | - |
| Stephen Yoo | M | 46 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 Jahre |
| Gaurav D. Shah | M | 49 |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 Jahre |
| Rachid Izzar | M | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jeffrey Capello | M | 69 | 3 Jahre | |
| William Jones | M | 68 | 2 Jahre | |
| Robert W. Pangia | M | 72 | 24 Jahre | |
| Lynn Schenk | F | 79 | 25 Jahre | |
| Trevor Anthony Mill | M | 53 | 9 Jahre | |
| Kleem Chaudhary | M | 48 | 1 Jahre | |
| Philipp Von Rosenstiel | M | - | 6 Jahre | |
| Charbel Haber | M | - | 3 Jahre | |
| Stacy Lindborg | M | 53 | 8 Jahre | |
| Stephanie Dyson | F | - | - | |
| Steve Doares | M | - | 10 Jahre | |
| F. Edmondson | M | 58 | 6 Jahre | |
| Michael Mano | M | 47 | 2 Jahre | |
| Karoline Shair | M | - | 2 Jahre | |
| Ferenc Tracik | M | 60 | 3 Jahre | |
| Jonathan Anderman | M | - | 1 Jahre | |
| Daniel Karp | M | 46 | 2 Jahre | |
| Anirvan Ghosh | M | 60 | 3 Jahre | |
| Mark Hernon | M | - | 4 Jahre | |
| Mahalakshmi Radhakrishnan | M | - | 4 Jahre | |
| Suzanne E. Murray | F | 49 | - | |
| Ralph Kern | M | 67 | 5 Jahre | |
| Paul McKenzie | M | 58 | 3 Jahre | |
| Matthew Calistri | M | - | - | |
| Samantha Haeberlein | M | - | 5 Jahre | |
| Wildon Farwell | M | 49 | - | |
| Richard Rudick | M | 73 | 6 Jahre | |
| Jesse M. Cedarbaum | M | - | 5 Jahre | |
| Michael Ehlers | M | - | - | |
| Christopher Henderson | M | - | 6 Jahre | |
| David Caouette | M | - | - | |
| Jeremy Duffield | M | 55 | 6 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 37 | 88,10% |
| Schweiz | 5 | 11,90% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Samantha Vieira
- Persönliches Netzwerk